Search

Displaying results 4121 - 4130 of 4235 in total
  1. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  2. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

  3. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  4. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site...

  5. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  6. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

  7. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  8. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

  9. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin and thereby preserving human immune cells by protecting against destruction of host cells mediated ...

  10. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).